ArriVent BioPharma, Inc. Common Stock

AVBPNASDAQUSD
31.20 USD
0.05 (0.18%)🟢PRE MARKET (AS OF 07:31 PM EDT)
🟢Market: OPEN

AVBP is currently priced at $31.20. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. AVBP is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Aug 26, 2026.

Open?$31.21
High?$32.72
Low?$29.72
Prev. Close?$31.14
Volume?326.3K
Avg. Volume?485.1K
VWAP?$31.06
Rel. Volume?0.67x
Bid / Ask
Bid?$26.22 × 100
Ask?$35.78 × 100
Spread?$9.56
Midpoint?$31.00
Valuation & Ratios
Market Cap?1.5B
Shares Out?49.3M
Float?31.3M
Float %?67.3%
P/E Ratio?N/A
P/B Ratio?4.19
EPS?-$3.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Employees
77
Market Cap
1.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-01-26
Address
18 CAMPUS BLVD.
NEWTOWN SQUARE, PA 19073-3269
Phone: 240-780-6356
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
10
Piotroski F-Score?0/9Weak
Altman Z-Score?30.92Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?26.25%Squeeze Risk
Short Interest?8.2M
Days to Cover?21.8
Free Float31.3M
Avg Daily Volume378.0K
Settlement Date2026-08-14
Financial Health
Current Ratio?14.16Strong
Quick Ratio?14.16Strong
Cash Ratio?5.56Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
43
4.19FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-7.7CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-44.6%WEAK
ROA?
S&P
3
-41.5%WEAK
Cash Flow & Enterprise
FCF?$-108348000
Enterprise Value?$1.4B
Fundamentals ratios updated end of day